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Abstract: Recent studies support the hypothesis of a close aetiological and pathogenic association between the presence 
of patent foramen ovale (PFO) and cryptogenic stroke. The therapeutic options currently used in the treatment of these 
patients range from standard antiaggregation and standard-dose anticoagulation to the percutaneous occlusion of the PFO. 
The use or recommendation of treatment is based both on clinical risk factors associated with PFO, such as age, detection 
of states of hypercoagulability and previous history of stroke, and on the risks associated to right-to-left shunt (RLSh) and 
PFO, such as the size of PFO, magnitude of RLSh and the presence of atrial septal aneurysm (ASA). However, there is 
currently no consensus regarding the most suitable treatment and it is surprising to observe the widespread use of certain 
therapeutic approaches which are not supported by clinical evidence.  
In this revision, we analyse the relevance of PFO in cryptogenic stroke, consider the main evidence available for 
determining the best management of these patients and make diagnostic and therapeutic management recommendations. 
Keywords: Patent foramen ovale, right-to-left shunt, cryptogenic stroke, transcranial Doppler, echocardiography. 
INTRODUCTION 
  Between 30 and 40% of ischaemic strokes are of 
undetermined aetiology even after adequate study and this 
percentage is even higher in the case of stroke in young 
patients [1]. The presence of patent foramen ovale (PFO) has 
been suggested in numerous studies
 as a potential cause of 
paradoxical embolism and, in particular, of cerebral emboli 
in stroke of unknown origin [2-21]
 (Table I). Some of these 
studies have shown an association between the size of PFO, 
the magnitude of right-to-left shunt (RLSh), and the presence 
of atrial septal aneurysm (ASA) with increased stroke risk 
[22]. However, few studies have analysed the risk of 
recurrence and, particularly, the risk of recurrence in relation 
to factors involved in a first stroke and, as such, the best 
treatment for patients with PFO has yet to be established. 
This article aims to review the involvement of PFO in 
crypto-genic stroke and its relevance in stroke recurrence, 
and to reflect upon the current therapeutic options for 
patients with this anomaly. 
BACKGROUND 
  Paradoxical embolism from the venous to the arterial 
systems through RLSh may be secondary to the presence of 
atrial septal or ventricular defects, pulmonary arteriovenous 
malformations, and, fundamentally, to the existence of a 
PFO. The PFO is a channel that is open during the foetal 
period and is the normal pathway of venous blood from the 
right to left cardiac cavities, before heading on, avoiding the 
pulmonary bed, towards the placenta, where it is oxygenated. 
After birth, the PFO is sealed functionally due to there being 
greater pressure in the left atrium than in the right atrium and  
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so the venous blood now heads from the right atrium to the 
pulmonary bed and, after crossing this filter, moves on to the 
left atrium. Permanent closure, by the adhesion of the septum 
primum to the septum secundum, typically occurs in the first 
three months after birth. However, there is a large group of 
people for whom the foramen ovale remains permeable. PFO 
is detected in 27-35% of normal hearts in autopsy studies 
[23,24] (Fig. 1), in 10-26% of healthy individuals by transoe-
sophageal echocardiography with contrast (c-TEE) and in 
25-35% through transcranial Doppler with contrast (c-TCD). 
The diameter of the PFO in autopsy studies in normal hearts 
oscillates between 1 and 19 mm, with a mean of 4.9 mm. 
The pathological relevance of these apparently inconse-
quential diameters becomes clear when we consider that an 
embolus of just 1 mm is sufficient to occlude a large cortical 
arterial branch and that an embolus of 3 mm is sufficient to 
occlude the middle cerebral artery causing a massive 
hemispheric infarction. 
  Paradoxical embolism was first described by Cohnheim 
in 1877 [25]. In 1972, by which time just 128 cases had been 
described worldwide, four necessary criteria were proposed 
for the acceptance of paradoxical embolism. These included 
the demonstration of venous thrombosis or of pulmonary 
embolism together with an increase in the pressure in the 
right cardiac cavities. In 1988 two studies were published 
which led to a reevaluation of the importance of PFO [2,3]. 
Both used contrast echocardiography in finding a 40-50% 
prevalence of PFO in cryptogenic stroke in young patients in 
comparison with 10-15% in healthy controls. Since then, 
many studies have confirmed the close association between 
PFO and ischaemic stroke (Table I). 
  Although paradoxical embolism, which is the passage of 
a thrombus from the peripheral venous system to the left 
cardiac cavities through the PFO, seems to be the most likely 
mechanism in patients with cryptogenic stroke associated to 
PFO, other potential mechanisms should also be considered. Patent Foramen Ovale in Cerebral Infarction  Current Cardiology Reviews, 2010, Vol. 6, No. 3    163 
One proposed mechanism is in situ thrombus formation 
within the foramen ovale channel itself. Alternatively, 
patients with PFO may be more susceptible to atrial fibril-
lation, due to an altered atrial electrical substrate [26]. 
Finally, we need to consider the possibility that patent 
foramen ovale discovered in patients with cryptogenic stroke 
might be incidental as has been argued to be the case by 
Kent D. et al. in one third of patients by applying Bayes’ 
theorem [27].  
HOW TO DETECT PFO USING CONTRAST 
ECHOCARDIOGRAPHY AND TRANSCRANIAL 
DOPPLER  
  PFO is detected by showing the passage of air micro-
bubbles from the right to the left cardiac cavities after the 
endovenous administration of echo contrast. Although there 
are commercially available echo contrasts, the technique 
using saline contrast has been validated and has the advan-
tages of being inexpensive, safe and available. Detection of 
RLSh through a PFO can be performed with c-TTE, c-TEE 
and c-TCD. As c-TEE detects approximately twice as many 
PFO’s as c-TTE, it is considered as being the diagnostic 
reference test.  
TEE Protocol 
  As part of the routine aetiological study of a patient who 
has suffered an ischaemic stroke, patients should undergo a 
complete transthoracic study before TEE evaluation. In 
general, TEE study is performed after topical anaesthesia of 
the oropharynx and mild sedation with intravenous mida-
zolam (0.5 to 1.5 mg). The echoscope is entered into the 
oesophagus, and the tip is tilted to permit a clear image of 
the atrial septum at the level of the fossa ovalis. Contrast 
material is prepared and injected into the antecubital vein as 
described in the TCD protocol below. The contrast 
examination is performed by studying the horizontal and the 
longitudinal views with the patient breathing normally and 
during a Valsalva manoeuvre. A PFO is diagnosed when 
microbubbles are detected in the left atrium within three 
cardiac cycles of their appearance in the right atrium. On the 
other hand, when microbubbles appear after the third beat 
these should normally be attributed to intrapulmonary shunt. 
Although there is no consensus as how to classify RLSh by 
Table I.  Prevalence of PFO by Echocardiography and/or c-TCD and Characteristics of Different Published Studies 
Author   Year  Unselected  
patients 
Age 
Range (mean) 
Nº of Patients 
with Stroke 
% PFO patients 
c-TEE c-TCD 
RLSh 
Quantification 
 % PFO in 
Cryptogenic Stroke  
Controls 
n (% PFO) 
Lechat et al. [2]  1988  No  <55 (36)  60  40* n.p.  No  54  100 (10) 
Webster et al. [3]  1988  No  <44 (36.1)  40  50* n.p.  No  56  40 (15) 
Pearson [18]  1991  No  17-84 (59)  79  11.3 n.p.  No  11.3  No 
Hausmann [16]  1992  No  18-84 (52+/-10)  103  26.1 n.p  No  31.6  116 (21.6) 
de Belder [17]  1992  No  16-84  104  21.1 n.p.  No  26  94 (3.2) 
Cabanes et al. [6]  1993  No  <55 (40.2)  100  43 n.p.  No  56.3  50 (18) 
Ranoux et al. [5]  1993  No  <55 (38.6)  68  47 n.p.  No  57  No 
Schminke et al. 
[12] 
1995  Yes  18-87 (57)  100  37 39  Yes  55  No 
Molins et al. [10]  1996  No  < 45  58  19* 34.5  No  42.8  No 
Di Tullio et al. [4]  1992  No  (61.4+/-15.7)  146  18* n.p.  No  42  No 
Klötzsch et al. [8]  1994  No  (61.4+/-15.7)  111  45 46  No  77.5  No 
Anzola et al. [11]  1995  No  18-75 (45+/-14)  72  52.5 47.5  No  n.d.  No 
Job et al. [9]  1994  No  < 45  74  51.3 47.3  Yes  66  63 (43) 
Jones et al. [13]  1994  Yes  (66±13)  220  16 n.p.  No  20  202 (15) 
Petty et al. [14]  1997  No  (60±3)  116  32 n.p.  No  40  No 
Homma et al. [20]  1994  No  n.d.  74  31 n.p.  Yes  44  No 
Nighoghossian 
[15] 
1996  No  23-59 (47+/-8.9)  118  25.4 n.p.  No  34  No 
Serena [21]  1998  Yes 
33-85 (64.8+/-
12) 
208 37.2
† 33.5  Yes  56.6  100 (28.2) 
n.p.= not performed. *Used only transthoracic echocardiography. 
†Included only cryptogenic stroke. 164    Current Cardiology Reviews, 2010, Vol. 6, No. 3  Serena et al. 
c-TEE, three groups are often accepted: small (less than10 
microbubbles); moderate, when too many microbubbles 
appear in the left atrium to be counted, but without being 
echogenic as in the right atrium; and, finally, severe, when 
microbubbles caused echogenicity with at least the same 
intensity in a part of the left atrium as in the right atrium 
[21]. Before examination with contrast, all patients undergo 
a complete TEE study to evaluate the size of the left atrium, 
the left atrial appendage, the presence of atrial spontaneous 
contrast and/or thrombi, atrial septum aneurysm, interatrial 
septum defect, and other potential sources of cardiac 
embolism. Finally, the probe is advanced 40 cm from the 
incisors, rotated through 180°, and slowly withdrawn to 
examine the descending thoracic aorta and the aortic arch for 
atherosclerotic plaques or thrombi as possible sources of 
embolization.  
  Although second harmonic imaging has increased TTE 
sensitivity to between 63% and 100% [28-30], c-TEE 
remains the standard echocardiographic technique, particu-
larly in young patients suffering from cryptogenic stroke.  
TCD Protocol 
  TCD examination may be performed either by using 
TCD or transcranial colour-coded duplex sonography. 
Although there tends not to be significant differences 
between the number of signals detected in the right and left 
middle cerebral arteries (MCA), TCD permits the simul-
taneous monitoring of both MCA‘s through the temporal 
window by the use of 2-MHz probes. For bilateral moni-
toring, TCD probes can be fitted using either a headband or 
light metal frame that allows the probes to be fixed firmly to 
the head. The contrast for the study is usually obtained by a 
mixture of sterile saline solution (9 mL) and air (1 mL), 
agitated between two 10-mL syringes, connected by a three-
way stopcock. The solution should be immediately injected 
with a 20-gauge/32-mm catheter placed in the antecubital 
vein to obtain a bolus of air microbubbles. This procedure 
should be performed during normal breathing and afterwards 
during a Valsalva manoeuvre, usually three times. The 
Valsalva manoeuvre can be standardized by asking the 
subjects to blow into a manometer until 50 to 60 mm Hg of 
pressure is reached and to maintain this pressure for a period 
of at least five to seven seconds. The bolus of air micro-
bubbles should be injected during Valsalva manoeuvre in 
one to two seconds at the end of this seven second period 
(Fig.  2). Subjects are previously instructed in the perfor-
mance of the Valsalva manoeuvre, the efficacy of which can 
be gauged by a reduction of at least 25% in the mean 
velocity of the MCA. The consensus reached at the 4th 
Meeting of the  
  European Society of Neurosonology and Cerebral 
Hemodynamics (ESNCH) [31] agreed that a time window 
from contrast infusion to signal detection in MCA cannot 
differentiate intracardiac and extracardiac shunt. From an 
aetiopathogenic point of view, an extracardiac shunt has the 
same relevance as an intracardiac shunt as a potential cause 
of stroke. RLSh should be suspected as being due to PFO 
when it is greater during the Valsalva manoeuvre than at rest 
whereas in extracardiac shunt the magnitude tends to be of a 
similar magnitude, and normally of longer duration, in the 
two states [32]. The most frequent extracardiac shunt, the 
arteriovenous pulmonary fistula, associated to an 18% 
incidence of stroke, is often clinically silent and can easily be 
suspected by c-TCD due to the specific profile of the RLSh 
when compared with that of the PFO [32-34] (Fig. 3 and web 
page video). As can be seen in Fig. 3 and the video, it only 
takes three seconds for massive RLSh after contrast infusion 
in basal conditions [34]. 
  Whether intracardiac or extracardiac, the relevance of 
RLSh depends on its magnitude, which is determined by 
counting the number of signals in the MCA. Patients are 
usually divided into 3 different groups on the basis of the 
maximum number of microbubble signals in the MCA in any 
single frame after intravenous injection of agitated saline 
solution: “normal” TCD study (if 0 signals were detected), 
“small” RLSh (10 signals), and “large” degree of shunt 
(more than 10 signals). In this last group, “shower” (more 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Prevalence of PFO in autopsy studies in subjects without heart disease. Patent Foramen Ovale in Cerebral Infarction  Current Cardiology Reviews, 2010, Vol. 6, No. 3    165 
than 25 microbubbles) and “curtain” (uncountable micro-
bubbles) are particularly relevant and have been associated 
with cryptogenic stroke in case-control studies [21] (Fig. 4). 
  There remains some discussion with regards to what the 
most appropriate methodology is to increase the sensitivity 
of RLSh detection using Valsalva manoeuvre and TCD. The 
consensus of the ESNCH recommended that Valsalva 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Summary of the RLSh detection methodology using TCD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Massive RLSh by transcranial colour coded duplex sonography detected 3 seconds after contrast infusion (agitated saline solution, 9 
mL of saline solution and 1 mL of air). Video can be downloaded at http://www.telefonica.net/web2/jserenal/pulmonaryshunt/fistula.htm 166    Current Cardiology Reviews, 2010, Vol. 6, No. 3  Serena et al. 
manoeuvre should be started 5 seconds after the beginning of 
the contrast injection. A comparison between different 
injection modes found increased sensitivity using injection 
before Valsalva manoeuvre with air/saline as a contrast 
agent. This is particularly true when a distal vein is used or 
when a short flexible tube is added to the needle in the 
antecubital vein. However, when the antecubital vein is used 
in the right arm without extension, a Valsalva manoeuvre 
and simultaneous contrast infusion increases the sensitivity 
of RLSh detection (Fig. 2).  
  Despite several studies having demonstrated that c-TCD 
has a sensitivity and specificity which is equal to or superior 
to c-TEE, this latter technique continues to be considered as 
the diagnostic test of reference given that it permits the direct 
visualisation of the size of the PFO and the demonstration of 
additional cardiac sources of cerebral embolism such as the 
presence of septal aneurism and atherosclerosis of the aortic 
arch. However, it should be noted that cTEE has certain 
limitations in the detection of RLSH: 10% of patients do not 
tolerate the performance of the test, the Valsalva manoeuvre 
is difficult to perform and standardise as TEE is a semi-
invasive technique often requiring patients to be sedated, is 
problematic for patients with stroke and swallowing 
difficulties, and, given that it is semi-invasive, is not suitable 
for systematic use or in control populations. In recent years, 
published studies have shown that in comparison with c-
TEE, c-TCD is more sensitive both in the detection and 
quantification of RLSh. Furthermore, c-TCD has the advan-
tages of studying the repercussion of RLSh directly in the 
target organ and of being easier to use, which makes it ideal 
both as a diagnostic test and for follow-up [7-11,21,31,35]. 
The prevalence of RLSh found using c-TCD in healthy 
controls (32%) is similar to the prevalence of PFO in autopsy 
studies [23,24], which lends support to the precision of c-
TCD in the detection of RLSh. Although the prevalence of 
RLSh is similar in ischaemic stroke and healthy populations, 
the prevalence is particularly high in the subgroup of young 
patients with a stroke of unknown origin [2,3,6,9,16,17]
 and, 
as we have recently been able to show, in patients of any age 
(Fig. 5) [21].  
  In the evaluation of the magnitude of RLSh it is essential 
to perform the Valsalva manoeuvre correctly. In early 
studies, c-TEE and c-TCD were carried our simultaneously 
and so incorrect or insufficient Valsalva manoeuvre affected 
both techniques. c-TCD is better than c-TEE in the detection 
and quantification of the magnitude of RLSh when both 
techniques are conducted independently both during the 
manoeuvre and in basal conditions. The most important 
limitation of c-TCD is the absence of a temporal bone 
window in 10% of patients who suffer stroke, a fact which 
particularly affects the older population although even in 
these cases the existence or not of RLSh can be established 
by insonating the internal carotid artery, the vertebral arteries 
or the basilar artery.  
  In the specific case of cryptogenic stroke, the usefulness 
of TEE is not so much in the detection of PFO as in the 
demonstration of other associated cardioembolic sources and 
in particular the existence of atrial septal aneurysm (ASA), 
which associated with PFO increases the risk of stroke 
through PFO or isolated ASA. In the opinion of the present 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Contrast TCD detected RLSh of less than 10 signals (upper panel), “shower” (middle panel), and “curtain” (lower panel) patterns in 
MCA after Valsalva manoeuvre. Patent Foramen Ovale in Cerebral Infarction  Current Cardiology Reviews, 2010, Vol. 6, No. 3    167 
authors, c-TCD is an important part of the ultrasonographic 
study that should be performed in patients with cryptogenic 
stroke particularly in young patients when paradoxical 
embolism should be suspected. The aetiological study of 
stroke must be accompanied by TTE or TEE.  
POTENTIAL MARKERS OF STROKE RECUR-
RENCE 
  The presence of RLSh is in itself an inadequate factor for 
the prediction of stroke risk due to the fact that 30% of the 
healthy population share this condition. Several studies have 
analysed the characteristics associated with a greater risk of 
ischaemic stroke: the size of the PFO
20 and, especially, the 
magnitude of the shunt have been found to increase risk. An 
average of 13.9 microbubbles is detected in the left atrium in 
patients with cryptogenic stroke as compared to 1.6 in 
patients with a known cause of stroke. De Castro et al. 
suggested the importance of RLSh magnitude in PFO on 
detecting those patients with PFO and cryptogenic stroke 
with ischaemic lesions in cranial CT showed a greater 
number of microbubbles in the left atrium than patients 
without cranial CT lesions. The c-TCD study has shown 
itself to be an efficient tool in the quantification of the shunt 
as was recognised by the previously mentioned Consensus 
Conference of the ESNCH [31]. Although the aetiopatho-
genic and therapeutic importance of the magnitude of shunt 
has not been fully established, the available results highlight 
the crucial importance of its quantification. Traditionally the 
importance of quantifying the magnitude of RLSh during the 
Valsalva manoeuvre is emphasised [18], however this is an 
aspect which could also be questioned. The magnitude of 
RLSh is typically higher with Valsalva manoeuvre than at 
rest but the presence of RLSh at rest may be of more 
clinically relevance. Patients with a shunt during quiet 
breathing have an increased time exposure to paradoxical 
embolism and should in theory be at increased risk of stroke 
recurrence. De Castro et al. [36] reported that the cumulative 
risk of cerebrovascular event recurrence at three years was 
higher (12.5%) in high risk PFO, defined as a mobile 
septum, and RLSh at rest than low risk PFO defined as RLSh 
only with Valsalva manoeuvre (event rate of 4.3%). A 
similar finding is suggested by a post-hoc analysis of the 
CODICIA study [37]. Stroke recurrence event rates, based 
on the RLSh magnitude groups defined by the maximum 
number of microbubble signals both during Valsalva 
manoeuvre and at rest in the whole population (n=486) and 
in the younger group (n=229), are presented in Fig. 6. 
Although no significant differences were obtained at rest in 
comparison with the main results, an increased risk of stroke 
recurrence was detected when only the curtain pattern at rest 
was considered.  
  However, the common identification of PFO in patients 
with established causes of stroke (atrial fibrillation, carotid 
stenosis) and the absence of factors which are traditionally 
associated with paradoxical embolism in patients with PFO 
and stroke (such as a previous history of thrombophlebitis; 
clinical criteria, ECG or echocardiographs showing pulmo-
nary hypertension; and especially a stroke onset associated 
with Valsalva manoeuvres increasing the pressure in the 
right cardiac cavities such as coughing or overexertion) have 
called into question the aetiopathogenic role of PFO in 
stroke. This is particularly the case in patients of advanced 
age, which is the population with the most frequent stroke 
risk and with the greatest number of associated vascular risk 
factors. In any case, although somewhat difficult to interpret, 
some studies have shown an association between PFO and 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Frequency of massive RLSh during Valsalva manoeuvre by age group in cryptogenic stroke, stroke of known aetiology, and in 
healthy controls. Number of patients in each group are given along the horizontal axis. Probability values representing the differences 
between groups are shown at the top of the bars.  168    Current Cardiology Reviews, 2010, Vol. 6, No. 3  Serena et al. 
cryptogenic stroke in older populations of patients (>55 y) 
[21,38]. PFO remained strongly associated with cryptogenic 
stroke after adjustment for stroke risk factors and so should 
be considered as a potential cause of stroke as the figures are 
similar to those found in younger patients (Fig. 5).  
  Amongst the potential anomalies associated to PFO 
detected by TEE that might explain increased stroke risk are 
ASA, Chiari networks (CN) and a prominent Eustachian 
valve (EV). Although there is no consensus as to the defi-
nition of ASA, it is generally accepted as being an excursion 
of the interatrial septum into either atrial cavity of at least 15 
mm [39]. In fact, PFO and its magnitude is a consequence of 
the presence of ASA. While the prevalence of ASA in the 
healthy population is only 1% [40], its prevalence in patients 
with massive RLSh reaches 30-40%. 
  Persistent EV or CN in adulthood has been suggested as 
one of the causes of RLSh in the absence of pulmonary 
hypertension [41,42]. The EV, which is derived from the 
right sinus venosus valve, has a semicircular shape and faces 
the anterior-inferior surface of the inferior vena cava to the 
atrial septum. CN, which have been found in 1.3% to 4% of 
autopsies, represent a large multi-perforated Eustachian 
valve with a network-like appearance. The EV and CN direct 
the flow of the inferior vena cava towards the foramen ovale 
during foetal life leading, in the case that it persists, to an 
adult predisposition to paradoxical embolism [22,43]. Large 
PFO and prominent EV or right atrial filamentous strands 
have been found more frequently in patients with ASA than 
those without (37.7% vs. 10.9%, p < 0.001 and 59.4% vs. 
43.1%, p = 0.02). In TEE studies, an EV is present in 48% of 
patients with cryptogenic stroke [44] and large CN are 
associated with PFO in 83% of cases [45].  
  Finally, prothrombotic states may lay behind paradoxical 
embolization through a PFO. Most studies have failed to find 
an association between cryptogenic stroke, PFO and 
prothrombotic diseases. However, recently factor V Leiden 
and prothrombin G20210A mutations have been described as 
being significantly more prevalent in patients with crypto-
genic stroke and PFO than in matched healthy controls (11% 
versus 2%; 95% CI, 0.04 to 0.94; p<0.05) or cryptogenic 
stroke without PFO (11% versus 1.1%; 95% CI, 1.09 to 109; 
P<0.05) [46]. 
RISK OF STROKE RECURRENCE IN CRYP-
TOGENIC ASSOCIATED WITH PFO 
  Although the association between PFO and cryptogenic 
stroke has been well established by many case-control 
studies [2-21] and the metaanalysis published by Overell et 
al. [22] confirms a consistent association in young patients 
(<55 y) between cryptogenic stroke and PFO (OR 6.00, 95% 
CI 3.72-9.68) and particularly of PFO+ASA (OR 17.09, 95% 
CI 2.19-133.46) when compared with stroke of known cause 
or healthy control PFO, the very few prospective studies that 
have analyzed the importance of PFO as a predictor of stroke 
or recurrence have given variable and sometimes conflicting 
results [47-50]. Furthermore, only one of these studies 
performed a randomised analysis of the efficacy of medical 
treatment in the secondary prevention of stroke and none has 
compared medical treatment with percutaneous occlusion in 
a prospective and randomised study (Table II).  
  The conclusions we can draw from the results of pub-
lished prospective studies in the literature are complementary 
to one another given that they have not been performed with 
a uniform design. The French study [48], which included 
only young patients (<55 years) with cryptogenic stroke, 
found an increase in the risk of recurrence in those patients 
with a combination of both PFO and ASA, independently of 
the size of the PFO, and no increase in the risk of patients 
with just either PFO or ASA. Despite the fact that there has 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). CODICIA Study. Stroke recurrence by RLSh magnitude at rest and during Valsalva manoeuvre in the younger population.  Patent Foramen Ovale in Cerebral Infarction  Current Cardiology Reviews, 2010, Vol. 6, No. 3    169 
been an ever more generalised tendency to close the PFO in 
young patients with PFO+ASA since the publication of this 
study, these results have not been confirmed by later studies 
(PICSS and CODICIA) and they were based on a subgroup 
of only 51 patients, who suffered six recurrences in four 
years.  
  Similarly to the French study, the PICSS study [49]
 was 
performed using contrast TEE in the evaluation of PFO, 
although in this case it was not limited to the study of young 
patients. The PICSS study used the design of the WARSS 
clinical trial that had randomised patients with non-
cardioembolic stroke in two branches of medical treatment 
(anticoagulation vs. antiplatelet) in an attempt to demonstrate 
that anticoagulation has greater efficacy in patients that 
habitually receive antiplatelet therapy. The PICSS study 
included 630 patients from a total of 2,206 randomized in the 
main study. Of these 630, 265 (42.1%) were classified as 
cryptogenic, 244 (38.7%) as lacunar, 68 (10.8%) large-
vessel, 27 (4.3%) other determined cause, and 26 (4.1%) as 
conflicting mechanism. The results of this, the only rando-
mised study did not show an increase in the risk of recur-
rence associated to PFO, whether with or without ASA, 
neither in patients with a known cause of stroke nor in the 
cryptogenic stroke group. The design of the PICSS study for 
the first time permitted a randomised evaluation of the 
efficacy of anticoagulant treatment in the prevention of 
recurrence and demonstrated that anticoagulation is not more 
efficient than antiplatelet therapy in the prevention of 
recurrence. 
  Finally, the Multicentre Study into RLSh in Cryptogenic 
Stroke (CODICIA Study) was a prospective, multicentre, 
observational study undertaken by the Cerebrovascular 
Diseases Group of the Spanish Neurological Society [50]. 
CODICIA included 486 patients older than 18 years with a 
recent cryptogenic ischaemic stroke. Functional outcome and 
stroke recurrence were evaluated at three months and yearly, 
during a mean time period of 729+/-411 days. The risk of 
recurrence in the CODICIA study was low and similar in 
patients with and without RLSh/PFO, independently of 
whether or not this was associated with ASA and whether 
the shunt was massive [21] (Fig. 7). 
  In addition to these four studies which had the objective 
of evaluating the risk of stroke recurrence, there are also two 
prospective studies that analysed the risk of a first stroke. 
The “Stroke Prevention: Assessment of Risk in a 
Community” (SPARC) study is the largest transoesophageal 
echocardiography-based study of stroke outcome in a 
random sample of a community [51]
 whereas the Northern 
Manhattan Study (NOMAS) have included the largest popu-
lation using transthoracic 2-dimensional echocardiography 
[52] (Table II). These studies are particularly interesting to 
Table II.  Annual Risk of Stroke Recurrence in Cryptogenic Stroke with or Without PFO. Prospective Studies 
Treatment   
n (%)  PFO +  PFO -  OR (CI 95%) 
Follow-up 
(months)  AAS Warfarin 
OR (CI 95%) 
Bogousslavsky J et al., 1996 
[47] 
140 (100)  2·4  ---  ---  36 (10-91)  No differences   
De Castro S et al., 2000 [36]
 
Low risk PFO subgroup 
High risk PFO subgroup 
160 (46·3) 
 
3·7 
1·4 
4·2 
4·5 
 
0·74 (0·30-1·81) 
 
31 (4-58)  Not evaluated  --- 
Mass JL et al., 2001 [48] 
PFO+ASA subgroup 
581 (37) 
 
1·5 
3·8 
1·8 
 
0·90 (0·46-1·82) 
2·98 (1·17-7·58) 
37·8 (9·7)  1·6  ---  --- 
Homma S et al., 2002 [49]
 
 PICSS-Cryptogenic patients 
265 (39)  7·15  6·35  1·14 (0·60-2·17)  24  9  4·8  0·52 (0·16-1·67) 
Serena J et al., 2008 [50]
 
CODICIA Study 
486 (41·2)  2·5  3·2  0·87 (0·39-1·93)  24·3 (13·7)  3·5  3·2  0·87 (0·39-1·93) 
Prospective studies in healthy population 
Meissner I et al, 2006 [51] 
 PFO alone 
 PFO+ASA 
 ASA alone 
585 
140 (24·3) 
6 (1·02) 
5 (1·1) 
 
2·14 
0 
2 patients 
 
2·17 
 
1·46 (0.74-2.88) 
3·72 (0·88-15·75) 
 
61·2 
    
Di Tullio M et al., 2007 [52] 
 PFO alone 
 PFO+ASA 
 ASA alone 
1,100  
164 (14·9) 
27 (2·7) 
8 (0·73) 
1·22 0·89   
1·64 (0·87-3·09) 
1·04, (0.14-7.74) 
3·66, (0.88-15.30) 
79·7 (28·0)       
The total number of cryptogenic strokes in the series, the percentage of PFO (between brackets), the time of follow-up as mean (SD) or median [quartiles] as appropriate. 170    Current Cardiology Reviews, 2010, Vol. 6, No. 3  Serena et al. 
analyse given that, as we have commented, 30% of the 
healthy population have a PFO. Meissner et al. conducted a 
study that included c-TEE in a population of 585 healthy 
subjects older than 45 years who were participants in the 
SPARC study, which was conducted in the Olmsted County 
population (a community of 1,475 inhabitants) as part of the 
Rochester Epidemiology Project in Rochester, Minnesota. 
After being followed for five years, the annual incidence of 
ischaemic events was 1.19% (6.9% in 5.1 years). The 
presence of PFO and its size were not predictors of a first 
stroke (RR: 1.46, 95% 0.74-2.88, p=0.28) as neither was the 
presence of ASA (RR: 3.72, 95% 0.88-15.71, p=0.07). In 
this last case there was a tendency towards statistical signi-
ficance but the figure is of just 11 patients out of a total of 
581 (1.9%) and there was no risk data in patients with 
ASA+PFO. Although this study was conducted in a popu-
lation with a relatively advanced age (>45 years, mean 66.9 
+/- 13.3), the data were adjusted for the presence of classical 
vascular risk factors. The results obtained offer further 
support to there being a low risk of stroke in the PFO popu-
lation and, hence, that primary prevention measures, invasive 
therapies such as percutaneous occlusion, and screening of 
particular risk groups is not at this time advisable. Similar 
results were found in the Northern Manhattan Study 
(NOMAS) [52]
 where PFO, whether alone or together with 
ASA, was not associated with an increased stroke risk in this 
multiethnic cohort. Although isolated ASA was associated 
with elevated stroke incidence, the authors advise that this 
result needs to be interpreted cautiously as again the sample 
is not representative (only eight patients out of a total sample 
of 1,100 who suffered two stroke recurrences in a mean time 
of follow-up of 6.6 years; HR 3.66, 95% CI 0.88 to 15.30, 
p=n.s.).  
  In the analysis of recurrence in other studies, the high 
risk found in the PICSS study particularly stands out 
(7%/year in comparison with 2-3% in the rest of the pros-
pective studies). This finding has been attributed to the 
greater prevalence of risk factors and the greater age of the 
patients in this study (59.0 +/- 12.2 years). The presence of 
PFO did not increase the risk of recurrence in cryptogenic 
stroke in young patients in the PICSS study whereas it did 
increase the risk in patients with an age of  65 years [53]. 
  So, how can we explain the discrepancy between the 
consistent results of case-control studies and the often 
negative results in prospective ones? Differences in study 
design could offer a partial explanation. An additional one 
might be that treatment with antiplatelet agents or 
anticoagulant could be effective in decreasing the risk of 
stroke recurrence associated with PFO detected in case-
control studies. On the other hand, a true increase in the risk 
of stroke recurrence associated to PFO might be counter-
balanced by a similar increase in the risk associated to other 
factors in patients without PFO [50]. Finally, the average 
follow-up duration of the prospective studies may be too 
short to evaluate the true risk of stroke recurrence associated 
to PFO.  
THERAPEUTIC MANAGEMENT OF PATIENTS 
WITH PFO 
  There is agreement in not recommending any therapeutic 
primary prevention measures in subjects with PFO. How-
ever, the ideal treatment of patients who have suffered a 
cryptogenic stroke with PFO as a potential cause has not 
been established. The options range from classical antipla-
telet treatment or anticoagulant therapy to surgical treatment.  
  Anticoagulant treatment in patients with cryptogenic 
stroke and PFO has become a frequent practice that has even 
been recommended in international conferences dealing with 
the subject. This has occurred particularly since the 
publication of the PFO-ASA French study in spite of the fact 
that the French study did not evaluate the efficacy of any 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Stroke recurrence by RLSh magnitude during Valsalva manoeuvre and presence of ASA in the whole and younger populations in 
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particular treatment (all of the patients received antiplatelet 
therapy) and no therapeutic recommendation was made. 
Regrettably anticoagulation is still used for this type of 
patients despite the fact that the PICSS study, whilst showing 
an increase in risk, did not find this treatment to be more 
effective. 
  After the PICSS study, only the CODICIA study has 
analysed the efficacy of different treatments in a prospective 
fashion (Table II). CODICIA was not specifically designed 
to investigate the efficacy of one or other treatment since the 
most adequate treatment was left to the criteria of the 
clinician. However, the volume of patients included (n=486) 
together with the habit of anticoagulating patients with 
RLSh/PFO made a sufficient volume of patients available in 
each group as to permit an approximation to the efficacy of 
the medical treatment although the limitations inherent in the 
design need to be borne in mind. In the CODICIA study, 
20.8% of patients received anticoagulant treatment for the 
prevention of recurrence. The conclusions of the CODICIA 
study are similar to the PICSS study: anticoagulant treatment 
is not significantly superior to antiplatelet therapy in the 
prevention of stroke recurrence. As is seen in Table II, there 
was a non-significant tendency to anticoagulation providing 
a greater benefit than antiplatelet therapy in the subgroup of 
patients of greater age with cryptogenic stroke but again 
there was no difference between patients with and without 
massive RLSh. Despite the tendency to a greater benefit of 
anticoagulation in older patients with cryptogenic stroke, 
which was also observed in the PICSS study, the results and 
design of the CODICIA, PICSS and WARSS studies do not 
justify its prolonged use at the present time, especially if we 
consider the secondary effects of warfarin and coumarin 
(risk: 2-3%/year, fatal 0.2%/year), which accumulate over 
time and are more serious than the risk of stroke recurrence 
due to the natural evolution of the disease. On the other 
hand, and as we have just commented, this benefit should be 
applicable equally to patients with cryptogenic stroke and 
PFO as to those who have cryptogenic stroke without PFO.  
  Endovascular treatment, usually with the insertion of a 
double disk or an umbrella that allows the PFO to be closed, 
is a technique that is being used with great enthusiasm 
despite it not being without risks and the fact that materials 
have not yet been developed that avoid deterioration and loss 
of efficacy over time. As has been reported in many studies 
[54,55], PFO closure is efficient and relatively safe. The 
incidence of major and minor complications are 1.5% and 
7.9% respectively. The annual rate of stroke is 1.98% (95% 
CI, 1.48 to 2.60) and the rate of stroke or death is 3.12% 
(95% CI, 2.32 to 4.11) in medically treated patients while in 
percutaneous closure of PFO these same figures are 0.19% 
(95% CI, 0.05 to 0.49) and 1.15% (95% CI, 0.46 to 2.37) 
[56,57]. Both metaanalyses comparing secondary prevention 
studies of transcatheter closure and medical therapy for PFO 
in cryptogenic stroke suggest the superiority of percutaneous 
occlusion in comparison with medical treatment. Khairy et 
al. conclude that percutaneous occlusion of PFO “may 
prevent a substantial proportion of cryptogenic strokes” 
whilst highlighting the need for randomised clinical trials 
[55]. However, the comparison of medical therapy with 
percutaneous closure is indirect as there are no results from 
clinical trials comparing medical and transcatheter closure 
treatment in a randomized setting and, in a recent collective 
analysis, there are no convincing data to indicate that the 
presence of PFO increases recurrent events in medically 
treated patients [57,58]. If we consider studies where PFO in 
cryptogenic stroke is compared with a non-PFO group 
[36,48-50,59], the relative risk of recurrent stroke or TIA 
ranges between 0.5 and 1.7, without statistically significant 
differences in the risk of recurrence in patient with and 
without PFO (RR 1.1, 95% CI 0.8 to 1.5; p=n.s.). 
  The key point would seem to be that percutaneous 
occlusion is probably the best therapeutic option if we are 
able to identify by clinical trials the precise risk group that 
would benefit from it. Meanwhile, the current evidence 
should advise against percutaneous occlusion of PFO other 
than in exceptional cases which should always be after a 
multidisciplinary evaluation of the patient and, in the opinion 
of the present authors, on being indicated by a neurologist 
who is an expert in vascular pathology. Having said this, 
Khairy’s metaanalysis should be interpreted with caution 
given the difficult task the authors faced in attempting to 
draw conclusions from such varied studies. The metaanalysis 
presents results derived from non-controlled studies, with 
different variables which were not previously defined, 
without homogeneity of the end-points, with highly variable 
methodologies in the detection of RLSh/PFO, and without 
safety committees nor follow-up of the registered cases. Fur-
thermore, the basal characteristics of the patients included 
are not homogenous between the studies. The prevalence of 
classical stroke risk factors such as smoking habit, diabetes, 
advanced age and a greater proportion of males is signifi-
cantly higher in those studies in which patients received a 
medical treatment, whilst in patients where percutaneous 
occlusion of the PFO was indicated, there were not only 
fewer classical risk factors but also a larger incidence of 
right-to-left shunt and subjects were more likely to have 
suffered more than one cerebrovascular event.  
  One aspect which has been little evaluated but which is 
very interesting when deciding which type of therapeutic 
intervention to undertake is the analysis of the consequences 
of suffering a stroke associated with RLSh/PFO. The fact 
that cryptogenic stroke associated with a RLSh presents a 
low annual risk of recurrence together with the lesser 
severity of stroke associated with RLSh shown by the 
CODICIA study [21,60] advises caution in the treatment 
selected for secondary prevention as, of course, we must not 
forget that any intervention must base itself on a risk/benefit 
analysis. As is shown in Fig. (8), stroke associated with 
RLSh/PFO has a better functional prognosis than crypto-
genic stroke without RLSH/PFO. This is due to the lesser 
volume of the infarct in patients with stroke and RLSh in 
comparison with the volume of the infarct of cryptogenic 
stroke without RLSh (14.3 ml [1.5-35.4] vs. 6.5 ml [1.3-
16.6]) and suggests that the mechanism of stroke in patients 
with and without RLSh/PFO is different. This hypothesis is 
supported by the greater prevalence of risk factors in patients 
with cryptogenic stroke without RLSh. The mechanisms of 
the stroke involved in RLSh appear less severe than those 
involved in patients without RLSh. We must be careful not 
to fall into the logical error of confusing the identification of 
a specific aetiology for a condition with the need to 
aggressively combat it.  172    Current Cardiology Reviews, 2010, Vol. 6, No. 3  Serena et al. 
FINAL RECOMMENDATIONS 
  Before indicating PFO closure, anticoagulation or 
antiplatelet therapy, we need to identify the subgroup of 
patients at high risk of stroke recurrence which may benefit 
from the application of these therapies. Several stroke 
associations, including the American Heart Association, 
American Stroke Association, American Academy of 
Neurology [58,61] and the European Stroke Organization 
(ESO) [62] recommend antiplatelet agents to prevent recur-
rent events (Class IIa, Level of Evidence B) whilst waiting 
for the results of ongoing clinical trials in PFO closure as 
there is currently insufficient data to make a recommen-
dation. A further reason for a cautious approach at present is 
that better technology is currently being developed which 
aims to seal the PFO in such a way that either no device is 
left in place or that any device that is implanted is either 
partially or completely bioabsorbable.  
  Anticoagulant therapy may be used in selected cases with 
high risk of thromboembolic events such as hypercoagulable 
states or evidence of deep venous thrombosis (Class IIa, 
Level of Evidence C). In clinical practice, PFO closure 
should be individualized and considered in young patients 
with recurrent stroke receiving medical treatment or in 
previously mentioned situations where anticoagulant treat-
ment is considered (Class IIb, Level of Evidence C). 
Ongoing trials have a low recruitment rate with a risk of bias 
if younger patients or those with severe PFO or associated 
anomalies are treated out of the trials. It is therefore 
important that effort should be made to randomize patients 
systematically in these trials (www.ClinicalTrials.gov) and 
to improve the collaboration between neurologists, basic 
scientists and cardiologists so that reliable results regarding 
the best treatment options can be established for our patients 
as soon as possible. 
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